…
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
GoodRx Holdings operates a digital marketplace for prescription drug price comparison and offers telehealth and subscription services. Long-term growth may be supported by persistent high drug prices, wider adoption of digital health and expansion of advertising and subscription revenue. Investors may find the company attractive because of its large consumer audience, recognizable brand and diversified monetization channels.
Material risks include regulatory or reimbursement changes that could reduce pharmacy or PBM fee income, rising competition from insurers and PBMs, and execution or data-privacy failures that could weaken user engagement.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 56.54M | 31.46M | -55.57M | -23.23M | -10.18M |
| Net income | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M |
| Selling general administrative | 113.96M | 117.86M | 125.52M | 144.79M | 154.69M |
| Selling and marketing expenses | 331.56M | 367.11M | 341.33M | 357.63M | 370.22M |
| Gross profit | 654.13M | 744.11M | 683.34M | 701.48M | 698.71M |
| Reconciled depreciation | 85.22M | 69.54M | 79.59M | 54.18M | 34.54M |
| Ebit | 99.14M | 84.38M | 1.16M | 11.01M | 13.41M |
| Ebitda | 184.36M | 153.92M | 108.82M | 65.19M | 48.00M |
| Depreciation and amortization | 85.22M | 69.54M | 107.67M | 54.18M | 34.60M |
| Non operating income net other | - | - | - | 9.27M | 0.06M |
| Operating income | 106.97M | 65.85M | -27.01M | 11.01M | 13.41M |
| Other operating expenses | 689.88M | 726.48M | 777.27M | 764.82M | 732.02M |
| Interest expense | 42.60M | 52.92M | 56.73M | 34.24M | 23.64M |
| Tax provision | 26.10M | 15.07M | -50.71M | 9.60M | 15.08M |
| Interest income | 10.93M | 23.27M | 29.14M | 9.27M | 0.06M |
| Net interest income | -31.67M | -29.65M | -24.69M | -24.97M | -23.58M |
| Income tax expense | -26.10M | 15.07M | -46.70M | 9.60M | 15.08M |
| Total revenue | 796.85M | 792.32M | 750.26M | 766.55M | 745.42M |
| Total operating expenses | 547.16M | 678.26M | 710.35M | 699.74M | 685.30M |
| Cost of revenue | 142.72M | 48.22M | 66.92M | 65.08M | 46.72M |
| Total other income expense net | -50.43M | -34.39M | -28.57M | -34.24M | -23.58M |
| Net income from continuing ops | 30.44M | 16.39M | 15.03M | -32.83M | -25.25M |
| Net income applicable to common shares | - | - | - | -32.83M | -25.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1404.06M | 1388.07M | 1588.80M | 1604.63M | 1607.62M |
| Intangible assets | 64.08M | 176.88M | 156.34M | 189.94M | 133.78M |
| Other current assets | 145.54M | 50.08M | 40.45M | 45.38M | 29.64M |
| Total liab | 787.80M | 663.41M | 826.84M | 789.80M | 775.95M |
| Total stockholder equity | 616.26M | 724.66M | 761.96M | 814.83M | 831.68M |
| Other current liab | 216.84M | 97.67M | 64.22M | 39.64M | 43.86M |
| Common stock | 0.03M | 0.04M | 0.04M | 0.04M | 0.04M |
| Capital stock | 0.03M | 0.04M | 0.04M | 0.04M | 0.04M |
| Retained earnings | -1410.57M | -1441.01M | -1457.40M | -1448.54M | -1415.71M |
| Other liab | - | - | - | 7.56M | 5.38M |
| Good will | 430.33M | 410.77M | 410.77M | 412.12M | 329.70M |
| Other assets | - | - | - | 8.16M | 6.01M |
| Cash | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total current liabilities | 246.00M | 123.90M | 122.56M | 76.32M | 81.11M |
| Current deferred revenue | - | - | 7.11M | 7.88M | 6.87M |
| Net debt | -202.28M | 95.04M | 38.77M | -40.14M | -238.78M |
| Short term debt | 9.75M | 10.64M | 14.96M | 11.10M | 12.88M |
| Short long term debt | 5.00M | 5.00M | 8.79M | 7.03M | 7.03M |
| Short long term debt total | 59.54M | 543.39M | 711.07M | 717.02M | 702.33M |
| Other stockholder equity | 2026.80M | 2165.63M | 2219.32M | 2263.32M | 2247.35M |
| Property plant equipment | - | - | - | 19.82M | 21.61M |
| Total current assets | 643.10M | 659.25M | 872.79M | 919.69M | 1088.83M |
| Net tangible assets | - | - | - | 814.83M | 831.68M |
| Net receivables | 235.75M | 160.83M | 160.04M | 117.14M | 126.41M |
| Long term debt | 483.26M | 486.71M | 647.70M | 651.80M | 655.86M |
| Inventory | - | - | 0.00M | - | -8.33M |
| Accounts payable | 19.41M | 14.14M | 36.27M | 17.70M | 17.50M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.04M | 0.04M |
| Retained earnings total equity | - | - | - | -1448.54M | -1415.71M |
| Non currrent assets other | 168.36M | 8.52M | 22.77M | 27.16M | 6.01M |
| Non current assets total | 760.96M | 728.81M | 716.01M | 684.95M | 518.80M |
| Capital lease obligations | 54.54M | 51.68M | 54.58M | 58.20M | 39.44M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -70.35M | -41.61M | -210.50M | -178.73M |
| Change to liabilities | - | - | - | -4.02M | 17.50M |
| Total cashflows from investing activities | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M |
| Net borrowings | -5.00M | -167.00M | -5.27M | -7.03M | -7.03M |
| Total cash from financing activities | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M |
| Change to operating activities | - | - | - | -20.79M | 27.95M |
| Net income | 25.01M | 16.39M | -8.87M | -32.83M | -25.25M |
| Change in cash | -186.53M | -223.95M | -84.87M | -183.94M | -30.48M |
| Begin period cash flow | 448.35M | 672.30M | 757.16M | 941.11M | 971.59M |
| End period cash flow | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total cash from operating activities | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 81.68M | 69.54M | 111.77M | 54.18M | 34.54M |
| Other cashflows from investing activities | -87.68M | -70.35M | -54.72M | -206.53M | -174.16M |
| Dividends paid | - | - | 0.00M | - | - |
| Change to account receivables | -88.02M | -2.33M | -26.47M | 1.38M | -43.95M |
| Sale purchase of stock | -206.94M | -158.84M | -103.97M | -101.72M | 35.02M |
| Other cashflows from financing activities | -23.78M | -11.64M | -58.15M | -20.64M | -23.50M |
| Change to netincome | - | - | - | 126.39M | 173.31M |
| Capital expenditures | 3.52M | 70.35M | 55.77M | 55.21M | 34.46M |
| Change receivables | - | - | - | 1.38M | -43.95M |
| Cash flows other operating | - | - | - | -1.73M | -14.93M |
| Cash and cash equivalents changes | - | - | - | -183.94M | -30.48M |
| Change in working capital | -56.44M | 2.09M | -21.94M | -20.29M | -11.80M |
| Stock based compensation | 58.66M | 99.03M | 104.82M | 120.23M | 160.46M |
| Other non cash items | 59.00M | 8.76M | 18.07M | 25.98M | 7.98M |
| Free cash flow | 164.38M | 113.55M | 82.53M | 91.57M | 144.32M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GDRX Goodrx Holdings Inc |
-0.17 4.79% |
3.48 | 58.17 | 10.29 | 1.52 | 1.88 | 1.86 | 8.53 |
| VEEV Veeva Systems Inc Class A |
-4.88 1.60% |
299.89 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
0.68 0.48% |
142.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-4.81 6.06% |
74.62 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.22% |
5.66 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
2701 Olympic Boulevard, Santa Monica, CA, United States, 90404
855 268 2822
697
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas Joseph Hirsch | Co-founder, Co-CEO & Director | 1971 |
| Mr. Trevor Bezdek | Co-founder, Co-CEO, Sec. & Director | 1978 |
| Mr. Karsten Ian Voermann | CFO & Principal Financial Officer | 1970 |
| Mr. Babak Azad | Chief Marketing Officer and SVP of Marketing & Communications | 1973 |
| Mr. Bansi Nagji | Pres of Healthcare | 1965 |
| Mr. Raj Beri | Chief Operating Officer | NA |
| Mr. Romin Nabiey | Chief Accounting Officer & Principal Accounting Officer | 1987 |
| Ms. Whitney Notaro | VP of Investor Relations | NA |
| Ms. Vina M. Leite | Chief People Officer | 1969 |
| Mr. Justin Fengler | Sr. VP of Corp. Strategy & Bus. Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.